Topical propranolol for treatment of superficial infantile hemangiomas - 14/11/12
Abstract |
Background |
“Wait-and-see” is a common principle for most superficial infantile hemangiomas (IHs) because of their expected involution. Topical propranolol has recently been reported to be an effective treatment for superficial IHs.
Objective |
The aim of this study was to evaluate the efficacy and safety of 1% propranolol ointment in the treatment of superficial IHs.
Methods |
A retrospective chart review was performed on 25 children (21 female and 4 male) with a median age of 4 months (range, 1-10 months). A total of 28 lesions were treated with 1% propranolol ointment. Topical propranolol was applied thrice daily for a mean duration of 21 weeks (range, 5-59 weeks). Changes in the size, texture, and color of the tumor were monitored and recorded at regular intervals. The treatment response was evaluated using a 3-point scale system: good, partial, and no response. Adverse effects after medication were evaluated and managed accordingly.
Results |
Of the 28 hemangiomas, 16 (57%) demonstrated good response, 9 (33%) showed a partial response, and 3 (10%) had no response. Among all the IHs, 90% showed either good or partial responses to topical 1% propranolol ointment treatment. No systemic complication was observed in any of the patients.
Limitations |
This report is a retrospective uncontrolled study.
Conclusions |
Topical therapy with 1% propranolol ointment may be a safe and effective method for the treatment of superficial IHs and can be used as an adjuvant treatment measure during the wait-and-see period.
Le texte complet de cet article est disponible en PDF.Key words : β-adrenergic receptor blocker, basic fibroblast growth factor, infantile hemangioma, propranolol, safety, vascular endothelial growth factor
Plan
Funding sources: None. |
|
Conflicts of interest: None declared. |
Vol 67 - N° 6
P. 1210-1213 - décembre 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?